Biosimilars

The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.

Latest News

FDA Approved. | Image Credit: wladimir1804 - stock.adobe.com
FDA Approves Denosumab Biosimilars Stoboclo and Osenvelt

March 4th 2025

The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for osteoporosis and bone loss in various patient populations.

FDA Approved. | Image Credit: Nirusmee - stock.adobe.com
First Insulin Aspart Biosimilar Receives FDA Approval

February 20th 2025

Osteoporosis. | Image Credit: Nisit - stock.adobe.com
Denosumab Biosimilars Approved With Interchangeability to Address Osteoporosis, Fracture Risk

February 18th 2025

Insulin. | Image Credit: Sherry Young- stock.adobe.com
Biosimilar Insulin Linked to Lower Prices in Europe

February 12th 2025

FDA approved. | Image Credit: Olivier Le Moal - stock.adobe.com
FDA Approves Celltrion’s Tocilizumab-anoh, Biosimilar to Actemra

January 31st 2025

Continuing Medical Education
View All
April 27th 2025

New and Approved: FDA’s 2024 Drug Lineup

1.5 Credits / General Pharmacy
April 27th 2025

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

More News

Site Logo
August 7th 2017

What We're Reading: Switching to Generics; Cutting Opioid Production; Updating Alzheimer's Tests

AJMC Staff
Dr Alan Carter on Biosimilars in the Insulin Market
July 27th 2017

Dr Alan Carter on Biosimilars in the Insulin Market

Alan Carter, PharmD, principal investigator and senior advisor at MRIGlobal, and adjunct faculty at University of Missouri—Kansas City School of Pharmacy discusses the influence of biosimilars and follow-ons in the insulin market and their reliability should be validated.
Site Logo
July 21st 2017

CT-P6, a Trastuzumab Biosimilar, Shares the Safety and Efficacy Profile of Its Reference

Kelly Davio
CT-P6, a proposed trastuzumab biosimilar, is safe and effective as a neoadjuvant treatment in HER2—positive early breast cancer, according to research presented at the 2017 American Society of Clinical Oncology Annual Meeting.
Site Logo
July 21st 2017

Research Demonstrates Efficacy and Safety of Trastuzumab Biosimilar SB3

Kelly Davio
Research presented at the 2017 American Society of Clinical Oncology Annual Meeting showed that SB3, a proposed biosimilar to trastuzumab, has comparable efficacy, safety, immunogenicity, and pharmacokinetics to the reference product based on the breast pathological complete response.
Site Logo
July 21st 2017

Switching Study Reports Equivalence Between Filgrastim, Biosimilar in Breast Cancer

Surabhi Dangi-Garimella, PhD
After switching studies, research in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy has found clinical equivalence between filgrastim and its biosimilar, according to results presented at the 2017 Annual Meeting of the American Society of Clinical Oncology.
Site Logo
July 7th 2017

Biosimilars: 5 Latest Developments

Surabhi Dangi-Garimella, PhD
Biosimilar molecules have gained access to the US market, and providers and patients are steadily warming up to the idea of using these products, but challenges still exist. Here are 5 of the recent developments in the biosimilar landscape.
Site Logo
July 3rd 2017

What We're Reading: Interchangeable Biosimilars; Nevada's Health Insurance; Shortage for Allergies

AJMC Staff
This Week in Managed Care: June 16, 2017
June 16th 2017

This Week in Managed Care: June 16, 2017

This week, the top managed care news included a report from CMS that found 2 million people dropped Obamacare coverage after failing to pay their premiums; a study found the diabetes drug canagliflozin reduced cardiovascular risk; and the Supreme Court of the United States rules in favor of biosimilars.
Dr Edward Li Discusses the Benefit Biosimilars Can Have in Oncology
June 4th 2017

Dr Edward Li Discusses the Benefit Biosimilars Can Have in Oncology

The impact that generics have on bringing down the cost of branded drugs needs to happen in the biologics space so the industry can save money and improve access to medications and population outcomes, according to Edward Li, PharmD, MPH, BCOP, of the University of New England.
The Importance of Real-World Data in Type 2 Diabetes
May 30th 2017

The Importance of Real-World Data in Type 2 Diabetes

Understanding the DUAL VII Findings in Type 2 Diabetes
May 30th 2017

Understanding the DUAL VII Findings in Type 2 Diabetes

Impact of Cardiovascular Data in Type 2 Diabetes
May 30th 2017

Impact of Cardiovascular Data in Type 2 Diabetes

Access to Therapeutic Combinations in Type 2 Diabetes
May 30th 2017

Access to Therapeutic Combinations in Type 2 Diabetes

Hypoglycemia: An Unrecognized Complication in Diabetes
May 30th 2017

Hypoglycemia: An Unrecognized Complication in Diabetes

Clinical Evidence of Insulin Degludec in Type 2 Diabetes
May 30th 2017

Clinical Evidence of Insulin Degludec in Type 2 Diabetes

Formulary Access to Insulins in Type 2 Diabetes
May 30th 2017

Formulary Access to Insulins in Type 2 Diabetes

Deciding Among Insulin Therapies for Type 2 Diabetes
May 30th 2017

Deciding Among Insulin Therapies for Type 2 Diabetes

Practical Decisions in Type 2 Diabetes
May 30th 2017

Practical Decisions in Type 2 Diabetes

Barriers to Insulin Therapy in Type 2 Diabetes
May 30th 2017

Barriers to Insulin Therapy in Type 2 Diabetes

Role of GLP-1/Insulin Combinations
May 30th 2017

Role of GLP-1/Insulin Combinations

Formulary Decisions and GLP-1/Insulin Combinations
May 30th 2017

Formulary Decisions and GLP-1/Insulin Combinations

Cardiovascular Considerations in Antidiabetic Therapies
May 30th 2017

Cardiovascular Considerations in Antidiabetic Therapies

Appropriate Access: Payer Perspective on Newer Insulins
May 30th 2017

Appropriate Access: Payer Perspective on Newer Insulins

Evidence With Ultra–Long Acting Insulins
May 30th 2017

Evidence With Ultra–Long Acting Insulins

Barriers to Traditional Insulin Therapy
May 30th 2017

Barriers to Traditional Insulin Therapy

Formulary Management: Antidiabetes Medications
May 30th 2017

Formulary Management: Antidiabetes Medications

Juggling Multiple Factors When Selecting Therapy
May 30th 2017

Juggling Multiple Factors When Selecting Therapy

Adherence Matters When Weighing a Single Injection
May 30th 2017

Adherence Matters When Weighing a Single Injection

The Advantages of Insulin, GLP-1 Combinations
May 30th 2017

The Advantages of Insulin, GLP-1 Combinations

Glycemic Control Is the Bottom Line
May 30th 2017

Glycemic Control Is the Bottom Line

<1
...
11121314151617181920>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo